SEC Form 4 · accession 0001179110-15-016635
SUNESIS PHARMACEUTICALS INC · SNSS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dayton Misfeldt
Director
Period of report
Dec 21, 2015
Accepted (ET)
Dec 21, 2015 · 9:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001061027
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 21, 2015 | P | 1,717,275 | $0.84 | A | 7,234,441 | I | See footnotes. |
| Common StockF1,F3 | Dec 21, 2015 | P | 32,725 | $0.84 | A | 137,859 | I | See footnotes. |
| Common StockF1,F4 | holding | — | — | — | 1,515 | I | See footnote. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person is a Managing Director of Bay City Capital LLC, a Delaware limited liability company ("BCC"). BCC is the manager of Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"). Management V is the general partner of Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V") and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held. Mr. Misfeldt, BCC and Management V disclaim beneficial ownership with respect to the securities reported in this Form 4, except to the extent of their pecuniary interest therein.
- F2The securities are held by Fund V.
- F3The securities are held by Co-Investment V.
- F4The securities are held by BCC.